About

About Holy Stone Healthcare Co., Ltd. Holy Stone Healthcare Co., Ltd. (4194.TW) was established in Taipei in January 2001. Since 2009, the company has focused on a biopolymer drug delivery platform. Our R&D team has successfully developed “Hyaluronan Drug Delivery (HDD)” technology, which is a composition of hyaluronic acid in combination with a drug. This technology has been applied in the development of our new drug and medical device portfolio. About Holy Stone Healthcare Co., Ltd. Holy Stone Healthcare Co., Ltd. (4194.TW) was established in Taipei in January 2001. Since 2009, the company has focused on a biopolymer drug delivery platform. Our R&D team has successfully developed “Hyaluronan Drug Delivery (HDD)” technology, which is a composition of hyaluronic acid in combination with a drug. This technology has been applied in the development of our new drug and medical device portfolio. Holy Stone Healthcare Co., Ltd. (Listed in Taiwan Stock Exchange as HSHC, 4194.TW), pioneers in Hyaluronan based delivery systems, is a subsidiary of Holy Stone Enterprise Co., Ltd. (3026.TW). Our proprietary platform enables CD44-mediated site-selective uptake of hyaluronan-drug conjugates to where the drug is needed in a localized tissue. We offer tailored HA polymers to carry poorly water soluble and/or systemic-labile payloads that require localized tissue exposure. Our platform assets covering neurodegeneration, oncology, autoimmune diseases, retinal diseases, and RNA delivery are with proven efficacy in human and animals as illustrated below: •HylNeuro™ (ND108E) – CNS-targeted delivery across BBB for neurodegeneration •HylTargis™ (CA102N)– CD44-targeted delivery for solid tumors •HylMusa™ (IBD98-M)– Mucosal healing and anti-inflammation in GI tract •HylRetinX™ (AMD112)– Oral delivery across BRB for retinal diseases •HylCaryo™ –HA nanoparticle system for RNA/nucleic acid delivery and releasing ☆ Partnering Goals We are actively seeking out-licensing opportunities and/or strategic partnerships to co-develop our CNS, oncology, and ophthalmology assets. We are also offering payload conjugation services for your specific payloads for targeted delivery including RNA therapeutics. The detailed status of the assets is described below: 1. ND108E (HylNeuro™ ): Alzheimer’s Disease Therapy A CNS-targeted HA conjugate designed to restore cognition in post-menopausal Alzheimer's patients. • Preclinical Data: Reversal of learning and memory deficits in behavioral models • Mechanism: Amyloid plaque reduction confirmed by PET imaging; increased spine density and restored ChAT activity • Status: IND-enabling studies in progress 2. CA102N (HylTargis™): Solid Tumor Therapy A dual-pathway (PI3K/mTOR + MAPK) HA conjugate targeting high-CD44 tumors, including KRAS G12D-mutant PDAC, TNBC, and mCRC. • Clinical Data: Phase I in mCRC showed prolonged PFS, improved DCR, and strong tolerability • Differentiation: >300 hrs tumor retention, 10x dose reduction with maintained efficacy • Next Steps: ODD application for PDAC; expansion to other tumor types 3. IBD98M (HylMusa™): Ulcerative Colitis Therapy An oral, multi-layer coated pellet combines HA and mesalamine for targeted colonic delivery. • Mode of Action: Forms a resorbable HA barrier over inflamed mucosa while delivering mesalamine locally • Clinical Status: Phase IIa showed significant symptom relief with a reduced drug burden; Phase IIb/III in preparation 4. AMD112 (HylRetinX™): Oral Wet AMD Therapy An oral HA conjugate with anti-angiogenic effects, designed to eliminate the need for intravitreal injections. • Efficacy: Demonstrated significant lesion size reduction in a laser-induced CNV model • Next Steps: Optimization of oral formulation and MOA confirmation underway ＃ Let’s Talk Please connect with us via appointments in the business forum 1 on 1 meeting, or visit our booth #2887 for more information on our data packages. Holy Stone Healthcare Co., Ltd. (Listed in Taiwan Stock Exchange as HSHC, 4194.TW), pioneers in Hyaluronan based delivery systems, is a subsidiary of Holy Stone Enterprise Co., Ltd. (3026.TW). Our proprietary platform enables CD44-mediated site-selective uptake of hyaluronan-drug conjugates to where the drug is needed in a localized tissue. We offer tailored HA polymers to carry poorly water soluble and/or systemic-labile payloads that require localized tissue exposure. Our platform assets covering neurodegeneration, oncology, autoimmune diseases, retinal diseases, and RNA delivery are with proven efficacy in human and animals as illustrated below: •HylNeuro™ (ND108E) – CNS-targeted delivery across BBB for neurodegeneration •HylTargis™ (CA102N)– CD44-targeted delivery for solid tumors •HylMusa™ (IBD98-M)– Mucosal healing and anti-inflammation in GI tract •HylRetinX™ (AMD112)– Oral delivery across BRB for retinal diseases •HylCaryo™ –HA nanoparticle system for RNA/nucleic acid delivery and releasing ☆ Partnering Goals We are actively seeking out-licensing opportunities and/or strategic partnerships to co-develop our CNS, oncology, and ophthalmology assets. We are also offering payload conjugation services for your specific payloads for targeted delivery including RNA therapeutics. 🎯 The detailed status of the assets is described below: 1. ND108E (HylNeuro™ ): Alzheimer’s Disease Therapy A CNS-targeted HA conjugate designed to restore cognition in post-menopausal Alzheimer's patients. • Preclinical Data: Reversal of learning and memory deficits in behavioral models • Mechanism: Amyloid plaque reduction confirmed by PET imaging; increased spine density and restored ChAT activity • Status: IND-enabling studies in progress 2. CA102N (HylTargis™): Solid Tumor Therapy A dual-pathway (PI3K/mTOR + MAPK) HA conjugate targeting high-CD44 tumors, including KRAS G12D-mutant PDAC, TNBC, and mCRC. • Clinical Data: Phase I in mCRC showed prolonged PFS, improved DCR, and strong tolerability • Differentiation: >300 hrs tumor retention, 10x dose reduction with maintained efficacy • Next Steps: ODD application for PDAC; expansion to other tumor types 3. IBD98M (HylMusa™): Ulcerative Colitis Therapy An oral, multi-layer coated pellet combines HA and mesalamine for targeted colonic delivery. • Mode of Action: Forms a resorbable HA barrier over inflamed mucosa while delivering mesalamine locally • Clinical Status: Phase IIa showed significant symptom relief with a reduced drug burden; Phase IIb/III in preparation 4. AMD112 (HylRetinX™): Oral Wet AMD Therapy An oral HA conjugate with anti-angiogenic effects, designed to eliminate the need for intravitreal injections. • Efficacy: Demonstrated significant lesion size reduction in a laser-induced CNV model • Next Steps: Optimization of oral formulation and MOA confirmation underway ＃ Let’s Talk Please connect with us via appointments in the business forum 1 on 1 meeting, or visit our booth #2887 for more information on our data packages.